目的 探讨莫西沙星治疗慢性阻塞性肺疾病急性加重期(AECOPE)的疗效.方法 选取2015年3月至2017年4月在我院治疗的AECOPD患者113例,根据治疗方案分为莫西沙星组(n=62)和左氧氟沙星组(n=51),观察两组治疗疗效、肺功能、超敏C反应蛋白(hs-CRP)、白细胞介素-8(IL-8)及肿瘤坏死因子α(TNF-α)水平及细菌清除情况.结果 莫西沙星组治疗总有效率为79.03%,优于左氧氟沙星组,差异有统计学意义(P<0.05);莫西沙星组第一秒用力呼气容积(FEV1)和第一秒用力呼气容积占用力肺活量的比值(FEV1/FVC)分别为(2.40±0.46)L和(70.11±7.13)%,明显高于左氧氟沙星,差异有统计学意义(P<0.05);两组治疗后hs-CRP、IL-8及TNF-α均较治疗前有所降低,差异有统计学意义(P<0.05);莫西沙星组治疗后hs-CRP为(7.06±2.14)mg/L,明显低于左氧氟沙星组,差异有统计学意义(P<0.05);莫西沙星组细菌清除率为84.38%,明显高于左氧氟沙星组,差异有统计学意义(P<0.05).两组患者均未出现严重不良反应.结论 莫西沙星治疗AECOPD有较好的效果,可作为治疗AECOPD的首选药物.%Objective To investigate the efficacy of moxifloxacin in the treatment of acute exacerbation of chronic ob-structive pulmonary disease( AECOPD) . Methods 113 patients with AECOPD treated in our hospital from March 2015 to April 2017 were selected and divided into two groups according to the treatment protocol:moxifloxacin group(n=62)and levofloxacin group (n=51). The therapeutic effect,lung function,the levels of hs-CRPU,IL-8 and TNF-α,and the bacterial clearance condition were observed in the two groups. Results The total effective rate of moxifloxacin group was 79. 03%,which was better than that of levo-floxacin group(P<0. 05);In moxifloxacin group,the FEV1 and FEV1 / FVCC ratio were(2. 40 ± 0. 46)L and(70. 11 ± 7. 13)%,re-spectively,significantly higher than those in levofloxacin group ( P <0. 05 );The bacterial clearance rate of moxifloxacin group was 84. 38%,significantly higher than that of levofloxacin group(P<0. 05). There were no serious adverse reactions in both groups. Con-clusion Moxifloxacin has a good effect on AECOPD and can be used as the first choice in the treatment of AECOPD.
展开▼
